Literature DB >> 23835504

Is routine appendectomy at the time of primary surgery for mucinous ovarian neoplasms beneficial?

Tomer Feigenberg1, Allan Covens, Zeina Ghorab, Nadia Ismiil, Valérie Dubé, Reda S Saad, Mahmoud A Khalifa, Sharon Nofech-Mozes.   

Abstract

UNLABELLED: The question whether the appendix should be removed at the time of surgery for apparent early-stage ovarian cancer is controversial. Removal of the appendix in the setting of mucinous histologic type is primarily driven by the existing challenge to distinguish between primary ovarian mucinous neoplasm and metastatic appendiceal carcinoma to the ovary.
OBJECTIVES: To evaluate the value of an appendectomy at the time of surgery for ovarian mucinous borderline tumors or carcinoma.
METHODS: A retrospective single institute-based study was conducted. We identified patients who were operated on by a gynecologic oncologist for an abnormal pelvic mass, which was diagnosed as mucinous adenocarcinoma or mucinous borderline tumor between January 2000 and December 2010. Cases were included in the study if an appendectomy was performed at the time of initial surgery.
RESULTS: Seventy-seven cases meeting the inclusion criteria were identified. The ovarian mass of 11 patients (14%) was diagnosed as metastatic appendiceal carcinoma involving the ovary. Evidence of metastatic disease, abnormal-looking appendix, or pseudomyxoma peritonei, were identified at the time of surgery for all of these cases. The condition of 30 patients (39%) and 36 patients (47%) were diagnosed as mucinous borderline ovarian tumor and invasive or microinvasive mucinous ovarian carcinoma, respectively. Evidence of metastasis from the ovary to the appendix was not identified in any of the cases.
CONCLUSIONS: Our data suggest that in cases of apparent early-stage mucinous ovarian borderline tumors and cancer, adding an appendectomy at the time of surgery is not warranted in the absence of a grossly abnormal appendix or evidence of metastatic disease.

Entities:  

Mesh:

Year:  2013        PMID: 23835504     DOI: 10.1097/IGC.0b013e31829b7dca

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  3 in total

1.  Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.

Authors:  Kevin M Elias; S Intidhar Labidi-Galy; Allison F Vitonis; Jason L Hornick; Leona A Doyle; Michelle S Hirsch; Daniel W Cramer; Ronny Drapkin
Journal:  Gynecol Oncol       Date:  2013-12-14       Impact factor: 5.482

2.  International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers.

Authors:  Jennifer J Mueller; Henrik Lajer; Berit Jul Mosgaard; Slim Bach Hamba; Philippe Morice; Sebastien Gouy; Yaser Hussein; Robert A Soslow; Brooke A Schlappe; Qin C Zhou; Alexia Iasonos; Claus Høgdall; Alexandra Leary; Roisin E O'Cearbhaill; Nadeem R Abu-Rustum
Journal:  Int J Gynecol Cancer       Date:  2018-06       Impact factor: 3.437

3.  ROR1 expression correlated with poor clinical outcome in human ovarian cancer.

Authors:  Huilin Zhang; Jinrong Qiu; Chunping Ye; Dazhen Yang; Lingjuan Gao; Yiping Su; Xiaojun Tang; Ning Xu; Dawei Zhang; Lin Xiong; Yuan Mao; Fengshan Li; Jin Zhu
Journal:  Sci Rep       Date:  2014-07-24       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.